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Abstract
Aminoglycoside antibiotics target the ribosomal decoding A-site and are active against a broad spectrum of bacteria. These
compounds bind to a highly conserved stem-loop-stem structure in helix 44 of bacterial 16S rRNA. One particular
aminoglycoside, paromomycin, also shows potent antiprotozoal activity and is used for the treatment of parasitic infections,
e.g. by Leishmania spp. The precise drug target is, however, unclear; in particular whether aminoglycoside antibiotics target
the cytosolic and/or the mitochondrial protozoan ribosome. To establish an experimental model for the study of protozoan
decoding-site function, we constructed bacterial chimeric ribosomes where the central part of bacterial 16S rRNA helix 44
has been replaced by the corresponding Leishmania and Trypanosoma rRNA sequences. Relating the results from in-vitro
ribosomal assays to that of in-vivo aminoglycoside activity against Trypanosoma brucei, as assessed in cell cultures and in a
mouse model of infection, we conclude that aminoglycosides affect cytosolic translation while the mitochondrial ribosome
of trypanosomes is not a target for aminoglycoside antibiotics.
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Introduction
Aminoglycoside antibiotics show broad-spectrum antibacterial
activity and are a common choice for treatment of serious
infections due to gram-negative bacilli, including endocarditis,
sepsis, pneumonia, and pyelonephritis [1]. Among the aminogly-
coside antibiotics, paromomycin has also been shown to be
effective against some protozoa and cestodes. The cost of
paromomycin is low, making it a particular good drug candidate
in countries that carry a burden of high parasitic infection rates.
While paromomycin is out of use as an antibacterial, it is marketed
as an oral treatment for amoebiasis and giardiasis. Paromomycin is
also used in combination therapy as a topical treatment for
cutaneous leishmaniasis [2]. Recently, paromomycin was licensed
as a treatment for visceral leishmaniasis, the most severe form of
leishmaniasis (reviewed in [3]).
Aminoglycosides exert their antibacterial activity by binding to
a highly conserved region in helix 44 of bacterial 16S-rRNA [4].
We have previously reconstructed the drug target site of protozoan
cytosolic ribosomes in chimeric bacterial ribosomes to demonstrate
that the decoding site of cytosolic Leishmania ribosomes is
susceptible to paromomycin but not to various other aminogly-
cosides [5]. These results have been recently confirmed by studies
that showed specific paromomycin binding to the decoding site of
Leishmania cytosolic ribosomes by surface plasmon resonance
analysis [6].
While these studies have collectively provided a molecular
rationale for the antileishmanial activity of paromomycin, these
findings did not address whether in addition the Leishmania
mitochondrial ribosome is targeted by aminoglycosides. Recent
data have demonstrated that mitochondrial translation is essential
for both the procyclic and the bloodstream form of Trypanosoma
brucei and that consequently mitochondrial protein synthesis may
represent an important drug target throughout the life cycle
of trypanosomes [7]. There is, however, some inconsistency in
the literature with regards to the effect of paromomycin on
mitochondrial protein synthesis in Leishmania. For instance
Maarouf et al. [8] have reported that paromomycin interferes
with mitochondrial protein synthesis in Leishmania, whereas
Horvath et al. [9] found no effect of paromomycin on mito-
chondrial translation.
Structural analysis of the Leishmania mitochondrial ribosome has
revealed a remarkable morphologic similarity to the eubacterial
ribosome [10]. However, the homolog of bacterial 16S rRNA
helix 44 in trypanosome mitochondria is truncated in comparison
to its bacterial counterpart, although the proximal part constitut-
ing the decoding site and the aminoglycoside-binding site is fully
retained (Fig. 1). This is not surprising as the ribosomal decoding
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ribosome, and it is universally conserved across all phylogenetic
domains of life including organelles. At the same time, the
mitochondrial rRNA of trypanosomes carries unique signatures
within its decoding site sequence. Not only is this rRNA motif
significantly different from bacterial 16S rRNA, it also shows a
considerable sequence difference between the two closely related
genera Leishmania and Trypanosoma (Fig. 1). The distinctive
structural features of the mitochondrial decoding site make it
difficult to predict its functional susceptibility to compounds that
bind to the bacterial decoding site.
Here we reconstructed the mitochondrial decoding sites of
Leishmania and Trypanosoma in bacterial ribosomes to analyze their
susceptibility to aminoglycoside antibiotics and to allow for a
comprehensive evaluation of the therapeutic potential of this class
of drugs against trypanosome parasites. Based on the susceptibility
pattern of chimeric ribosomes mimicking the ribosomal decoding
sites of Trypanosoma, we assessed the antiprotozoal activity of
paromomycin in cultures of T. brucei and in a mouse model of
infection.
Materials and Methods
Ethics statement
Animal experiments were carried out in compliance with Swiss
federal law (TSchG) and cantonal by-laws (TSchV Basel-Stadt). All
protocols and procedures were reviewed and approved by the local
veterinary authorities of the Kanton Basel-Stadt (Permit Number: 739).
RNA secondary structure alignment
All rRNA nucleotides discussed in this study are numbered
according to their homologous position in E. coli 16S rRNA. 9S
rRNA genes of L. donovani, L. major, L. amazonensis, L. tarentolae, T.
brucei, and T. cruzi (Genbank accession numbers FJ416603,
EU140338, HM439238, M10126, M94286, and DQ343645,
respectively) were used for rRNA sequence alignments of the
mitochondrial decoding sites. 18S rRNA genes of L. donovani, L.
major, L. mexicana, L. amazonensis, L. braziliensis, L. tarentolae, T. brucei,
and T. cruzi (accession numbers FR799614, FR796423,
GQ332360, GQ332354, GQ332355, M84225 AL929603, and
FJ001665, respectively) were used for rRNA sequence alignments
of the cytosolic decoding sites (Fig. S1).
Figure 1. Secondary-structure comparison of small-subunit rRNA sequences. Phylogenetic comparison of the rRNA helices that correspond
to the proximal portion of helix 44 in bacterial 16S rRNA, which is an integral part of the ribosomal decoding site.
doi:10.1371/journal.pntd.0001161.g001
Author Summary
Rational design of novel therapeutics relies on the
knowledge and understanding of potential drug targets.
Historically, the majority of therapeutics have not been
rationally designed, but empirically discovered. Paromo-
mycin, an aminoglycoside with antibacterial activity, has
been found to show considerable activity against leish-
maniasis, a disease caused by the protozoan parasite
Leishmania. However, the mechanisms of aminoglycoside
action against protozoan parasites have in part remained
unclear. In this study we demonstrate that the cytosolic
ribosome is the preferred drug target, and that the
mitochondrial ribosome does not contribute to the
antiprotozoal activity of aminoglycosides. As the cytosolic
ribosome of Trypanosoma, the causative agent of sleeping
sickness and Chagas disease, resembles that of Leishmania,
we tested the efficacy of paromomycin against Trypano-
soma. We found that paromomycin not only inhibits the
growth of Trypanosoma in culture, but also suppresses
trypanosomiasis in a mouse infection model. Our results
point to the cytosolic ribosome as a promising drug target
for antiprotozoal drug development.
Paromomycin Susceptibility of Kinetoplastidal rRNA
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Recombinant Mycobacterium smegmatis strains with chimeric
ribosomes were constructed by previously described gene
replacement procedures. 1) rRNA fragments coding for mutant
rRNA were generated by PCR mutagenesis and cloned into a
suitable vector to result in chromosomal gene replacement via
homologous recombination with donor DNA by selection of the
mutant genotype [11]. 2) Plasmid replacement in a Drrn knockout
strain of M. smegmatis mc
2-155. DNA sequences coding for
chimeric rRNA were generated by PCR, cloned into a plasmid
coding for a full rRNA operon, and used to replace the wild-type
rRNA sequence in M. smegmatis by means of plasmid exchange [5].
Strains and plasmids used in this study are listed in Tables S1 and
S2. Successful rRNA replacement was controlled by sequence
analysis.
Drug susceptibility of chimeric ribosomes
Recombinant M. smegmatis strains were studied for susceptibility
to paromomycin, neomycin, gentamicin, and tobramycin (Sigma
Aldrich). Minimal inhibitory concentrations (MIC) were deter-
mined by broth microdilution tests as described previously [12].
The gentamicin used in this study is a mixture of gentamicin C1,
gentamicin C1a, and gentamicin C2 in a 45:35:30 ratio. The
chemical structures of aminoglycoside antibiotics are provided as
Fig. S2.
In vitro assays
Bloodstream forms of Trypanosoma brucei rhodesiense STIB900 and
axenic amastigote forms of L. donovani (MHOM-ET-67/L82) were
used for the in vitro assays. Cytotoxicity was assessed with rat
skeletal myoblasts (L6 cells). IC50 values were obtained using a
resazurin-based assay (alamarBlue) as described earlier [13]. The
following compounds were used as standards: melarsoprol (T.b.rho-
desiense), miltefosine (L. donovani), and podophyllotoxin (L6 cells).
Test compounds were dissolved in distilled water. Following
initial experiments the assay duration time was extended to 96 hrs,
120 hrs and 144 hours for L. donovani to demonstrate in vitro
activity of paromomycin. For the assays with extended duration a
subculture was prepared after 72 hrs by transferring 10 ml of the
initial assay culture to 100 ml fresh medium containing the
corresponding compound concentration.
In vivo efficacy against T.b.brucei STIB795
Groups of 4 female NMRI mice (Harlan Netherlands) of 22–
25 g were infected by the intraperitoneal route with 10
4
bloodstream form of T. brucei brucei STIB795 per mouse.
Paromomycin was formulated in physiological saline solution
and administered i.p. in a volume of 10 ml kg
21.Treatment was
initiated on day 3 post-infection. The mice were monitored for
parasitaemia 24 hrs after the last treatment (day 7) and again on
day 10 and 14 post-infection. Once parasitaemia exceeded 10
7/ml
the animals were euthanized. The day of relapse was used as
endpoint.
Results
The parasitic trypanosomes (Kinetoplastida: Trypanosomati-
dae) include the genera Trypanosoma and Leishmania. We have
previously reconstructed the aminoglycoside drug binding pocket,
i.e. the decoding A-site, of trypanosome cytosolic ribosomes in
bacteria [5]. To do so, we have replaced the proximal stem of helix
44 in bacterial 16S rRNA, i.e. nucleotides homologous to positions
1408–1416 and 1484–1491 in bacterial 16S rRNA, with the
corresponding cytosolic rRNA sequences present in Leishmania and
Trypanosoma species (Fig. 1 and 2). In the same study, we
demonstrated the specific activity of paromomycin against
Leishmania and Trypanosoma chimeric cytosolic ribosomes [5].
For a comprehensive analysis of trypanosomal susceptibility to
2-deoxystreptamines, we reconstructed the mitochondrial decod-
ing A-sites of Leishmania and Trypanosoma in bacterial ribosomes.
The mitochondrial rRNA sequence, and in particular the
decoding A-site is considerably different between Leishmania and
Trypanosoma (Fig. S1). Base pair 1409—1491, which is considered
key in aminoglycoside susceptibility, is characterized by an UNC
interaction in Leishmania versus an A—U base pairing in
Trypanosoma (Fig. 1). Furthermore, the mitochondrial A-site of
Leishmania and Trypanosoma exhibits a unique 1406C—1495G base
pairing. This is in contrast to the cytosolic decoding A-site, which
shows the typical 1406U—1495U interaction that is universally
conserved across the three domains of life including organelles.
Attempts to reconstruct the entire mitochondrial trypanosome
A-site in bacteria as a 27-nucleotide helix comprising residues
1404–1416 and 1484–1497 were unsuccessful. We thus recon-
structed the trypanosome homologue of helix 44 as two mutant
chimeric ribosomes: one with a 19-nucleotide helix of Leishmania
and Trypanosoma mitochondrial rRNA corresponding to M.
smegmatis positions 1408–1416 and 1484–1493, and one mutant
recombinant carrying the characteristic trypanosome mitoriboso-
mal 1406C—1495G pair (Fig. 2).
Studying the bacterial recombinants revealed that the mito-
chondrial chimeras with the 19-nucleotide replacement are
susceptible to compounds with a 69-amino substituent, such as
neomycin, gentamicin, and tobramycin, and less susceptible to
paromomycin, which carries a 69-hydroxy substituent (Fig. 2; the
chemical structures of the tested 2-deoxystreptamines are provided
in Fig. S2). In addition, the Trypanosoma 19-nucleotide chimera was
found to be generally more susceptible to aminoglycosides than its
Leishmania counterpart reflecting the canonical base pair interac-
tion between residues 1409 and 1491 (Fig. 2). Recombinants
carrying the 1406C—1495G pair were susceptible to the 4,5-
disubstituted aminoglycosides neomycin and paromomycin, but
highly resistant to the 4,6-disubstituted aminoglycosides gentami-
cin and tobramycin (Fig. 2). From the combined results we
conclude that among the aminoglycosides tested, neomycin has
the highest activity against the protozoan mitoribosomes, while
gentamicin and tobramycin are virtually inactive.
The finding that the Trypanosoma ribosomal decoding sites are at
least as susceptible to paromomycin as those of Leishmania
ribosomes prompted us to determine the efficacy of aminoglyco-
sides against Trypanosoma in a cell culture assay. We found that
paromomycin suppressed growth of Trypanosoma brucei rhodesiense in
vitro (Table 1). Compared to T. brucei rhodesiense,I C 50 determina-
tions of paromomycin in L. donovani required extended assay
durations. Notably, the 50% inhibitory concentration (IC50)o f
paromomycin was more than tenfold lower with T. brucei than with
L. donovani (Table 1). To assess whether mitochondrial protein
synthesis is involved in paromomycin’s potent antiprotozoal
activity, we also studied the efficacy of neomycin against T. brucei.
Neomycin shows significant activity against Trypanosoma mito-
chondrial recombinant ribosomes but little activity against
Trypanosoma cytosolic chimeras (Fig. 2). Thus, if trypanosome
mitochondria were to be targeted by aminoglycosides, we would
expect neomycin to show activity against T. brucei. However,
compared to paromomycin, neomycin had no effect on the growth
of T. brucei (Table 1). Tobramycin, an aminoglycoside that is
inactive against both cytosolic and mitochondrial chimeric
ribosomes (Fig. 2), was used as a control and had no effect on
trypanosome growth in culture (Table 1).
Paromomycin Susceptibility of Kinetoplastidal rRNA
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paromomycin in the T. brucei brucei STIB795 mouse model of
infection. Paromomycin suppressed the growth of T. brucei in vivo
and increased the mean survival time even at the lowest dose
regimen of 100 mg per kg of body weight given for 4 days
(Table 2). However, high concentrations of paromomycin did not
fully eradicate the parasite in the mouse infection model, as
parasitemia relapsed once treatment was stopped.
Discussion
Protein synthesis is an established drug target in antibacterial
chemotherapy and has been considered as target for antiprotozoal
drugs [14]. Although the mechanisms of action of drugs targeting
the ribosome have still to be studied in more detail, it has become
clear that both cytosolic and organelle ribosomes represent
potential drug targets [15,16]. The plastidal ribosome is an
established drug target in Apicomplexa [17], and serves as target
for drugs such as clindamycin in the treatment of Toxoplasma [18]
or plasmodia infections [19].
Among the various aminoglycosides paromomycin has been
repeatedly found to be the most potent antiprotozoal compound.
In early studies, paromomycin showed good antiamoebic and
some antitrichomonal activity [20] whereas the related compound
neomycin, which differs from paromomycin by a single substituent
(amino instead of hydroxy group at position 69; Figure S2), was
poorly active against Entamoeba histolytica [21]. Likewise, paromo-
mycin was shown to be more potent against amoebiasis than
kanamycin, neomycin, and gentamicin, respectively, and in a
Table 1. Antiprotozoal activity of selected aminoglycoside
antibiotics in cell culture.
IC50 (mg/ml)
Assay duration (h)
T. brucei
rhodesiense L. donovani
Paromomycin 72 6.2 .90
96 ND
a 75.8
120 ND 62.2
144 3.3 54.5
Neomycin 72 .60 ND
Tobramycin 72 .60 ND
aND, not determined.
doi:10.1371/journal.pntd.0001161.t001
Figure 2. Aminoglycoside susceptibility of rRNA chimeras. Aminoglycoside susceptibility is expressed as minimal inhibitory concentrations
(MIC, mg/mL). The protozoan sequence part is boxed with the protozoan-specific nucleotides colored in blue.
doi:10.1371/journal.pntd.0001161.g002
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tamine that showed activity [22]. Until recently, leishmaniasis was
exclusively treated with sodium stibogluconate, pentamidine, or
amphotericin B, but such treatments are expensive and potentially
toxic. In contrast, paromomycin has been recently proposed as a
well-tolerated and affordable treatment for visceral leishmaniasis
(reviewed in [3]), which is still considered the second biggest
parasitic killer after malaria.
Aminoglycoside antibiotics are cationic compounds with a 2-
deoxystreptamine core that is glycosidically linked at position 4 to
a glucopyranosyl (Fig. S2). Additional amino sugars are attached
to either position 5 or 6 of the 2-deoxystreptamine moiety. Both
the 4,5- and 4,6-disubstituted aminoglycosides target the ribosome
by direct interaction with ribosomal RNA, affecting protein
synthesis by inducing codon misreading and by inhibiting
translocation of the tRNA-mRNA complex [23–25]. The binding
site is defined by a number of nucleotides in the proximal stem of
helix 44 in bacterial 16S rRNA (reviewed in [26]). Genetic and
biochemical studies showed that the following bases are particu-
larly relevant for aminoglycoside binding: A1408, C1409—
G1491, and U1406—U1495 [12,27–30].
We have previously emphasized the role of nucleotide 1408 in
aminoglycoside susceptibility by studies of a cytosolic rRNA
chimera of the trypanosome Blastocrithidia. This parasite carries a
ribosomal decoding site that is identical to that of Leishmania and
Trypanosoma with the exception of a 1408 adenosine instead of a
guanosine [5]. In line with structural predictions, the cytosolic A-
site of Blastocrithidia was found to be highly susceptible to all
aminoglycosides tested. In contrast, the aminoglycoside target site
in chimeric cytosolic ribosomes of Leishmania and Trypanosoma
showed drug susceptibility merely to paromomycin but not to
other aminoglycosides [5] (Fig. 2). These findings are in agreement
with previous observations that Leishmania cultured in vitro is
susceptible to paromomycin [31,32]. Maarouf et al [8] have
reported that paromomycin interferes with mitochondrial protein
synthesis in Leishmania, whereas Horvath et al. [9] found no effect
of paromomycin on mitochondrial protein synthesis. As a result,
the precise role of mitochondria in trypanosome susceptibility to
aminoglycosides has remained elusive.
The uracil-uracil opposition at position 1406—1495 is univer-
sally conserved across the three phylogenetic domains of life
including their organelle ribosomes. The trypanosome mitochon-
drial ribosomes are exceptional in that they are characterized by a
C—G base pair at 1406—1495. Any alteration of the U—U pair,
particularly in U1406, results in decreased susceptibility to 4,6-
substituted aminoglycosides such as gentamicin and tobramycin
[26]. This is most likely due to a distortion of the amino sugar
attached to position 6 of the aminocyclitol ring, thereby disrupting
its hydrogen bonds to G1405. The conformation of aminoglyco-
sides with an amino sugar attached to position 5 of the
aminocyclitol ring is such that no contacts are made with
G1405, and thus binding of 4,5-aminoglycsides is generally less
affected by base alterations in 1406—1495. Hence, with regards to
4,6-substituted compounds, the 1406C—1495G pair confers high-
level drug resistance (Fig. 2). It appears that the C–G pair alone
renders the mitochondrial ribosome of trypanosomes resistant to a
large number of aminoglycoside antibiotics, except the 4,5-
disubstituted aminoglycosides paromomycin and neomycin.
Neomycin has significant activity against the trypanosome
mitochondrial A-site in recombinant chimeric ribosomes. Among
the aminoglycosides tested, which include paromomycin, genta-
micin, and tobramycin, neomycin has the most potent antimitor-
ibosomal activity (Fig. 2). However, in accordance with previous
studies, we find that neomycin has no anti-trypanosomal activity in
cell culture in-vitro (Table 1). Together with recent results
demonstrating the essentiality of mitochondrial translation in the
life cycle of T. brucei, our findings indicate that mitochondrial
translation is not accessible to aminoglycosides. The organelles’
resistance to neomycin action apparently is not due to an intrinsic
resistance of the drug target structure, but most likely reflects
limited mitochondrial permeability.
The observation that the cytosolic ribosomes of Trypanosoma are
identical to that of Leishmania with respect to both rRNA sequence
of the drug binding site and aminoglycoside susceptibility
prompted us to test the efficacy of paromomycin against
Trypanosoma in vitro and in vivo. Paromomycin was the most
active antibiotic when compared to other aminoglycosides
targeting protein synthesis. Intriguingly, in the cell culture model
T. brucei showed significantly higher susceptibility to paromomycin
than Leishmania donovani. In the T. brucei STIB795 mouse model,
paromomycin treatment was able to suppress parasitemia and thus
significantly increase the mean survival time of infected mice,
suggesting that paromomycin inhibits the growth of T. brucei.
However, paromomycin treatment did not eradicate the pathogen
and relapse occurred in all tested animals after termination of
treatment. Apparently, the anti-trypanosomal activity of paromo-
mycin is sufficient to prevent Trypanosoma propagation and spread,
but by itself is insufficient to cure the disease. Together, the
findings reported here point to additional potential for antiproto-
zoal aminoglycosides beyond the currently established treatment
options.
Supporting Information
Figure S1 Sequence alignments of Leishmania and
Trypanosoma rRNA genes. Nucleotides coding for the rRNA
Table 2. In-vivo efficacy of paromomycin in the T. brucei brucei STIB795 mouse model.
Parasitemia positive
Dose regimen per kg (i.p.)
Treatment period (days post
infection) Day 7 Day10 Day 14 Mean survival time (days)
Control
a 4/4 6.5
46100 mg 3–6 4/4 9.3
46200 mg 3–6 3/4 4/4 13.5
106100 mg 3–12 0/4 4/4 16.0
106200 mg 3–12 0/4 0/4 4/4 22.0
aUntreated control used to determine the mean survival.
doi:10.1371/journal.pntd.0001161.t002
Paromomycin Susceptibility of Kinetoplastidal rRNA
www.plosntds.org 5 May 2011 | Volume 5 | Issue 5 | e1161helices depicted in Figure 1 are highlighted in yellow. Nucleotides
homologous to bacterial 16S rRNA residues 1408, 1492, and 1493
are colored in blue.
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Figure S2 Chemical structures of the 2-deoxystreptamines used
in this study.
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